ReviewMedComm2026
Generative Artificial Intelligence and Large Language Models in Clinical Oncology.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, and the increasing availability of multimodal biomedical data has created unprecedented opportunities for precision oncology. Recent advances in generative artificial intelligence (AI), particularly large language models (LLMs), have enabled new approaches for integrating heterogeneous data sources, including electronic health records, medical imaging, pathology, genomics, and clinical text. However, current studies remain fragmented across specific tasks, cancer types, and model architectures, and a comprehensive synthesis of how generative AI can support the entire oncology continuum is still lacking. This review provides an overview of generative AI in clinical oncology, covering LLMs, generative adversarial networks, diffusion models, and multimodal foundation models. We summarize their methodological foundations and discuss applications in cancer diagnosis, prognosis prediction, treatment planning, patient management, and clinical trial optimization. Particular attention is given to multimodal data integration, synthetic data generation, clinical reasoning, and decision support, together with current challenges related to interpretability, reliability, data privacy, regulatory governance, and real-world implementation. By consolidating recent technological advances and clinical evidence, this review highlights future priorities toward safe, trustworthy, and clinically deployable intelligent oncology systems. Emerging agent-based architectures and human-AI collaborative workflows may further expand the clinical utility of generative AI in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.